[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": [
            "Neoplasms",
            "Solid Tumors",
            "Antineoplastic Agents",
            "MAPK",
            "ERK"
        ],
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "Astex Pharmaceuticals, Inc.",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Inclusion Criteria:\r\n\r\n        Subjects must fulfill all of the following inclusion criteria.\r\n\r\n          1. Able to understand and comply with study procedures, understand the risks involved in\r\n             the study, and provide written informed consent before any study-specific procedure is\r\n             performed.\r\n\r\n          2. Men or women 18 years of age or older.\r\n\r\n          3. Subjects with histologically or cytologically confirmed advanced solid tumors that are\r\n             metastatic or unresectable, who are refractory or have relapsed after treatment with\r\n             available therapies or for whom standard life-prolonging measures or approved\r\n             therapies are not available. In Phase 1 Part B and in the Phase 2 portion of the\r\n             protocol, subjects must also have documented gene alterations in the MAPK pathway as\r\n             detailed in the protocol.\r\n\r\n          4. In Phase 1 Part B of the protocol, subjects must have disease lesions that are\r\n             amenable to biopsy.\r\n\r\n          5. In the Phase 2 portion of the protocol, subjects must have measurable disease\r\n             according to RECIST v1.1.\r\n\r\n          6. Eastern Cooperative Oncology Group performance status 0 to 2.\r\n\r\n          7. Acceptable organ function as evidenced by the following laboratory data:\r\n\r\n               1. Aspartate aminotransferase (AST) and alanine aminotransferase \u22642\u00d7upper limit of\r\n                  normal (ULN) or \u22643 ULN in the presence of liver metastases.\r\n\r\n               2. Total serum bilirubin \u22641.5\u00d7ULN.\r\n\r\n               3. Absolute neutrophil count (ANC) \u22651500 cells/mm3.\r\n\r\n               4. Platelet count \u2265100,000 cells/mm3.\r\n\r\n               5. Calculated creatinine clearance (by the standard Cockcroft Gault formula) of \u226550\r\n                  mL/min or glomerular filtration rate of \u226550 mL/min.\r\n\r\n          8. Women of child-bearing potential (according to recommendations of the Clinical Trial\r\n             Facilitation Group [CTFG]; see protocol for details) must not be pregnant or\r\n             breastfeeding and must have a negative pregnancy test within 24 hours before the first\r\n             dose of study treatment. While receiving study treatment and for at least 5 half-lives\r\n             of ASTX029 or metabolite plus 30 days after completing treatment, women of\r\n             child-bearing potential must agree to practice highly effective contraceptive measures\r\n             (as described in the protocol) and must refrain from donating eggs (ova, oocytes) for\r\n             the purpose of reproduction.\r\n\r\n          9. Men with female partners of child-bearing potential (according to recommendations of\r\n             the CTFG; see protocol for details) must agree to, during the treatment period and for\r\n             at least 5 half-lives of ASTX029 or metabolite plus 90 days after completing\r\n             treatment, practice highly effective contraceptive measures (as described in the\r\n             protocol), not to father a child, and to refrain from donating sperm.\r\n\r\n        Exclusion Criteria:\r\n\r\n          1. Hypersensitivity to ASTX029 or excipients of the drug product.\r\n\r\n          2. Poor medical risk in the investigator's opinion because of systemic diseases in\r\n             addition to the cancer under study, for example, uncontrolled infections.\r\n\r\n          3. Life-threatening illness, significant organ system dysfunction, or other condition\r\n             that, in the investigator's opinion, could compromise subject safety or the integrity\r\n             of study outcomes or interfere with the absorption or metabolism of ASTX029.\r\n\r\n          4. Prior anticancer treatments or therapies within the indicated time window prior to\r\n             first dose of study treatment (ASTX029), as follows:\r\n\r\n               1. Cytotoxic chemotherapy or radiotherapy within 3 weeks prior. Palliative\r\n                  radiotherapy to a single lesion within 2 weeks prior. Any encountered\r\n                  treatment-related toxicities (excepting alopecia) not stabilized or resolved to\r\n                  \u2264Grade 1.\r\n\r\n               2. Monoclonal antibodies within 4 weeks prior. Any encountered treatment-related\r\n                  toxicities not stabilized or resolved to \u2264Grade 1.\r\n\r\n               3. Molecularly targeted drug or investigational drugs, without the potential for\r\n                  delayed toxicity, within 4 weeks of the first dose of study treatment or 5\r\n                  half-lives (minimum 14 days), whichever is shorter. Any encountered\r\n                  treatment-related toxicities (excepting alopecia) not stabilized or resolved to\r\n                  \u2264Grade 1.\r\n\r\n          5. Prior treatment with extracellular signal-regulated kinase (ERK) inhibitors.\r\n\r\n          6. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the\r\n             following conditions:\r\n\r\n               1. Abnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram (ECHO)\r\n                  or multiple-gated acquisition (MUGA) scan.\r\n\r\n               2. Congestive cardiac failure of \u2265Grade 3 severity according to New York Heart\r\n                  Association functional classification defined as patients with marked limitation\r\n                  of activity and who are comfortable only at rest.\r\n\r\n               3. Unstable cardiac disease including unstable angina or hypertension as defined by\r\n                  the need for overnight hospital admission within the last 3 months (90 days).\r\n\r\n               4. History or evidence of long QT interval corrected for heart rate (QTc),\r\n                  ventricular arrhythmias including ventricular bigeminy, complete left bundle\r\n                  branch block, clinically significant bradyarrhythmias such as sick sinus\r\n                  syndrome, second- and third-degree atrioventricular (AV) block, presence of\r\n                  cardiac pacemaker or defibrillator, or other significant arrhythmias.\r\n\r\n               5. Screening 12-lead electrocardiogram (ECG) with measurable QTc interval of \u2265470\r\n                  msec. (Fridericia's formula should be used to calculate the QTc interval\r\n                  throughout the study.)\r\n\r\n          7. Known history of human immunodeficiency virus (HIV) infection or seropositive results\r\n             consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV)\r\n             infection.\r\n\r\n          8. Known brain metastases, unless previously treated and stable for at least 3 months\r\n             with or without steroids.\r\n\r\n          9. Known significant mental illness or other conditions, such as active alcohol or other\r\n             substance abuse that, in the opinion of the investigator, predispose the subject to\r\n             high risk of noncompliance with the protocol treatment or assessments.\r\n\r\n         10. History or current evidence/risk of retinal vein occlusion (RVO) or central serous\r\n             retinopathy (CSR) including:\r\n\r\n               1. Presence of predisposing factors to RVO or CSR (eg, uncontrolled glaucoma or\r\n                  ocular hypertension, uncontrolled diabetes mellitus) or\r\n\r\n               2. Visible retinal pathology as assessed by ophthalmic examination at screening that\r\n                  is considered a risk factor for RVO or CSR such as:\r\n\r\n                    -  Evidence of optic disc cupping or\r\n\r\n                    -  Evidence of new visual field defects on automated perimetry or\r\n\r\n                    -  Intraocular pressure >21 mmHg as measured by tonography."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases\r\n      (ERKs) 1/2. ASTX029 has not been previously evaluated in human subjects. The Phase 1 portion\r\n      of this study will assess safety and determine the maximum tolerated dose, the recommended\r\n      Phase 2 dose (RP2D), and the recommended dosing regimen of ASTX029 administered orally. The\r\n      Phase 2 portion will assess preliminary clinical activity in tumors characterized by gene\r\n      aberrations in the mitogen-activated protein kinase (MAPK) signal pathway that may confer\r\n      sensitivity to ASTX029.",
        "official_title": "A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors",
        "_phase_sort_order": 3,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year",
                "name": "Efficacy - DCR",
                "description": "Disease control rate",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year",
                "name": "Efficacy - DOR",
                "description": "Duration of response",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year",
                "name": "Efficacy - OS",
                "description": "Overall survival",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year",
                "name": "Efficacy - PFS",
                "description": "Progressive-free survival",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year",
                "name": "Efficacy (Phase 2) - Response Evaluation Criteria in Solid Tumors using RECIST v1.1",
                "description": "Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2",
                "name": "Pharmacokinetic profile of ASTX029 - AUC",
                "description": "1) Area under the time-concentration curve",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2",
                "name": "Pharmacokinetic profile of ASTX029 - Cmax",
                "description": "2) Maximum plasma concentration",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2",
                "name": "Pharmacokinetic profile of ASTX029 - Cmin",
                "description": "3) Minimum plasma concentration",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2",
                "name": "Pharmacokinetic profile of ASTX029 - Half-life",
                "description": "5) Elimination half-life",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2",
                "name": "Pharmacokinetic profile of ASTX029 - Metabolites",
                "description": "6) Analysis of ASTX029 metabolites if applicable",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2",
                "name": "Pharmacokinetic profile of ASTX029 - Tmax",
                "description": "4) Time to reach maximum concentration",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "End of each dosing cycle (Day 21 of 21-day cycle)",
                "name": "Safety (Phase 1) - Dose-limiting toxicities including incidence of Treatment-Emergent Adverse Events",
                "description": "Number of subjects with dose-limiting toxicities",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Day 8 of Cycle 2",
                "name": "Target engagement in tumor tissues - pRSK",
                "description": "Inhibition of phosphorylated ribosomal s6 kinase protein in response to ASTX029 treatment in fresh tumor biopsies",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I_II",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 3,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03520075",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Positive",
                    "positive test result"
                ],
                "nci_thesaurus_concept_id": "C35682",
                "name": "Positive Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367",
                    "C36292"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25870",
                "name": "Transferase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C21281",
                    "C16612"
                ],
                "parents": [
                    "C21281"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Genes"
                ],
                "nci_thesaurus_concept_id": "C16612",
                "name": "Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25872",
                "name": "Kinase Family Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25871",
                    "C21281",
                    "C25870",
                    "C16612"
                ],
                "parents": [
                    "C25871"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25871",
                "name": "Phosphotransferase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C21281",
                    "C25870",
                    "C16612"
                ],
                "parents": [
                    "C25870"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Lab Value",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ERK",
                    "Extracellular Signal-Regulated Kinase Gene",
                    "MAPK",
                    "Mitogen-Activated Protein Kinase Gene"
                ],
                "nci_thesaurus_concept_id": "C26360",
                "name": "MAP Kinase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25872",
                    "C25870",
                    "C16612",
                    "C25871",
                    "C25873",
                    "C21281"
                ],
                "parents": [
                    "C25873"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C103223",
                "name": "Genetic Finding",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C77140"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "STK",
                    "Serine/Threonine Kinase Gene",
                    "Serine/Threonine-Protein Kinase Gene"
                ],
                "nci_thesaurus_concept_id": "C25873",
                "name": "Serine/Threonine Protein Kinase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25871",
                    "C25872",
                    "C21281",
                    "C16612",
                    "C25870"
                ],
                "parents": [
                    "C25872"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "ERK Alteration Positive",
                    "ERK Family Alteration Positive",
                    "ERK Family Gene Alteration Positive",
                    "Extracellular Signal-Regulated Kinase Family Gene Alteration Positive",
                    "MAPK Family Gene Alteration Positive",
                    "Mitogen-Activated Protein Kinase Family Gene Alteration Positive"
                ],
                "nci_thesaurus_concept_id": "C142130",
                "name": "MAPK Gene Alteration Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C25872",
                    "C25870",
                    "C21281",
                    "C16612",
                    "C36292",
                    "C25871",
                    "C77140",
                    "C3367",
                    "C35682",
                    "C25873",
                    "C26360",
                    "C103223"
                ],
                "parents": [
                    "C103223",
                    "C26360",
                    "C35682"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C21281",
                "name": "Enzyme Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": null,
        "current_trial_status_date": "2018-05-10",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Recurrent Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Malignant Solid Neoplasm",
                    "Metastatic Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Unresectable Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127156",
                "name": "Unresectable Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Advanced Solid Tumor",
                    "Advanced Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9270",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133737",
                "name": "Refractory Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C132146",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Neoplasm Recurrence",
                    "Recurrence",
                    "Recurrent Tumor",
                    "Recurrent"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4798",
                    "C9305"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "ASTX029-01",
        "active_sites_count": 12,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Drug",
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Agent"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C155785",
                        "name": "ERK 1/2 Inhibitor ASTX029",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C174048"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastics",
                            "Anti-Cancer Agents",
                            "Antineoplastic Drugs",
                            "Antiproliferative Agents",
                            "Tumor-Specific Treatment Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Tumor Agents",
                            "Antiproliferative Drugs",
                            "Cancer Drug",
                            "Anti-Tumor Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129824",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1404",
                        "name": "Protein Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C174048",
                        "name": "ERK Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129825",
                            "C61074"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Protein Antagonist",
                            "Anti-cancer Protein Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C61074",
                        "name": "Serine/Threonine Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1404"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Phase 1 Regimen 1",
                "description": "Dose escalation and expansion:\r\nRegimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase 1 Regimen 2",
                "description": "Dose escalation and expansion:\r\nRegimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase 2",
                "description": "ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2018-02018",
        "why_study_stopped": null,
        "brief_summary": "This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the\r\n      safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029\r\n      administered orally to subjects with advanced solid malignancies who are not candidates for\r\n      approved or available therapies.",
        "brief_title": "Study of ASTX029 in Subjects With Advanced Solid Tumors",
        "status_history": [
            {
                "status_date": "2018-05-10T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 300,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2018-05-10",
        "record_verification_date": "2023-03-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Randomized Controlled Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2023-12-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]